H.R. 2123 · 112th Congress
Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2011
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 112th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
GalleglySponsor34 cosponsors · 26 D, 8 R
D
Himes
DW
D
Wu
JG
R
Gerlach
EN
D
Norton
RD
D
DeLauro
MF
D
Fudge
SF
D
Farr
GP
D
Peters
JC
D
Conyers
HC
D
Clarke
EP
D
Pastor
CM
R
Miller
DK
D
Kildee
CM
D
Murphy
JT
D
Tierney
BF
D
Frank
EJ
D
Johnson
JS
D
Speier
JJ
D
Jackson
HC
R
Coble
TM
R
McCotter
CY
R
Young
CD
R
Dent
HB
D
Berman
NL
D
Lowey
AS
D
Schwartz
MC
D
Critz
JM
D
Moran
DP
D
Price
GC
D
Connolly
MR
D
Ross
CM
D
McCarthy
FW
R
Wolf
CS
R
Smith2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2011 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to establish and implement a hereditary hemorrhagic telangiectasia (HHT, a vascular genetic bleeding disorder that causes abnormalities of the blood vessels) initiative to assist in…
What it does: CRS summary · Introduced in House · Jun 3, 2011
Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2011 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to establish and implement a hereditary hemorrhagic telangiectasia (HHT, a vascular genetic bleeding disorder that causes abnormalities of the blood vessels) initiative to assist in coordinating activities to improve early detection, screening, and treatment of people who suffer from HHT, focusing on advancing research on the causes, diagnosis, and treatment of HHT and increasing physician and public awareness of HHT.
Directs the Secretary to establish the HHT Coordinating Committee to develop and coordinate implementation of a plan to advance research and understanding of HHT, including by: (1) conducting or supporting research across relevant National Institutes of Health (NIH) institutes, and (2) conducting evaluations and making recommendations regarding the prioritization and award of NIH research grants relating to HHT.
Requires the Director of the Centers for Disease Control and Prevention (CDC) to carry out activities with respect to HHT, including conducting population screening and establishing an HHT resource center to provide comprehensive education on, and disseminate information about, HHT to health professionals, patients, industry, and the public. Sets forth requirements for HHT population screening, including requiring the Director of CDC to designate and provide funding for HHT Treatment Centers of Excellence.
Requires the Administrator of the Centers for Medicare & Medicaid Services (CMS) to award grants for: (1) an analysis of the Medicare Provider Analysis and Review (MEDPAR) file to develop preliminary estimates on the totals costs to Medicare for items, services, and treatments for HHT; and (2) recommendations regarding an enhanced data collection protocol to permit a more precise determination of such costs.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2011
Latest action (Jun 16, 2011): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jun 3, 2011
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.